Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3.

[1]  G. McMahon,et al.  Expression of the Chemokine Receptor CXCR3 and Its Ligand IP-10 During Human Cardiac Allograft Rejection , 2001 .

[2]  L. Trentin,et al.  The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. , 1999, The Journal of clinical investigation.

[3]  H. Weiner,et al.  CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[4]  James G Krueger,et al.  Potential Role of the Chemokine Receptors CXCR3, CCR4, and the Integrin αEβ7 in the Pathogenesis of Psoriasis Vulgaris , 2001, Laboratory Investigation.

[5]  P. Libby,et al.  Differential Expression of the IFN-γ-Inducible CXCR3-Binding Chemokines, IFN-Inducible Protein 10, Monokine Induced by IFN, and IFN-Inducible T Cell α Chemoattractant in Human Cardiac Allografts: Association with Cardiac Allograft Vasculopathy and Acute Rejection1 , 2002, The Journal of Immunology.

[6]  K. Matsushima,et al.  Neutralization of IFN‐inducible protein 10/CXCL10 exacerbates experimental autoimmune encephalomyelitis , 2002, European journal of immunology.

[7]  R. Ravid,et al.  Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system , 2002, Journal of Neuroimmunology.

[8]  C. Mackay,et al.  The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. , 1998, The Journal of clinical investigation.

[9]  P. McCarthy,et al.  Chemokine and chemokine receptor gene expression indicates acute rejection of human cardiac transplants1 , 2003, Transplantation.

[10]  E. Bröcker,et al.  The C–X–C chemokine Mig is highly expressed in the papillae of psoriatic lesions , 1998, The Journal of pathology.

[11]  B. Aizenstein,et al.  Elevation of CXCR3‐Binding Chemokines in Urine Indicates Acute Renal‐Allograft Dysfunction , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  P. Loetscher,et al.  Lymphocyte‐specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization , 1998, European journal of immunology.

[13]  S. Kunkel,et al.  EncephalomyelitisDuring Experimental Autoimmune Accumulation in the Central Nervous System T Cell + Control of Encephalitogenic CD4 -Inducible Protein-10) g CXCL10 (IFN-and , 2001 .

[14]  W. Hancock,et al.  Requirement of the Chemokine Receptor CXCR3 for Acute Allograft Rejection , 2000, The Journal of experimental medicine.

[15]  D. Kolson,et al.  CXCR3 expression in human central nervous system diseases , 2001, Neuropathology and applied neurobiology.

[16]  A. T. Te Velde,et al.  Chemokine Receptor CXCR3 Expression in Inflammatory Bowel Disease , 2001, Inflammatory bowel diseases.

[17]  H. Weiner,et al.  IFN-Inducible Protein 10/CXC Chemokine Ligand 10-Independent Induction of Experimental Autoimmune Encephalomyelitis1 , 2004, The Journal of Immunology.

[18]  M. Burdick,et al.  Role of CXCL9/CXCR3 Chemokine Biology during Pathogenesis of Acute Lung Allograft Rejection 1 , 2003, The Journal of Immunology.

[19]  D. Adams,et al.  Differential expression of chemokines and chemokine receptors shapes the inflammatory response in rejecting human liver transplants. , 2001, Transplantation.

[20]  D. Mahad,et al.  Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis , 2002, Journal of neurology, neurosurgery, and psychiatry.

[21]  Ji Ming Wang,et al.  IL-2 and IL-12 Alter NK Cell Responsiveness to IFN-γ-Inducible Protein 10 by Down-Regulating CXCR3 Expression1 , 2002, The Journal of Immunology.

[22]  P. McCarthy,et al.  Chemokine and receptor-gene expression during early and late acute rejection episodes in human cardiac allografts , 2003, Transplantation.

[23]  E. Werner,et al.  Structure and Expression of the Human Small Cytokine B Subfamily Member 11 (SCYB11/formerly SCYB9B, alias I-TAC) Gene Cloned from IFNHuman gamma-Treated Monocytes (THP-1) , 1999 .

[24]  M. Burdick,et al.  Monokine Induced by IFN-γ Is a Dominant Factor Directing T Cells into Murine Cardiac Allografts During Acute Rejection1 , 2001, The Journal of Immunology.

[25]  J. Demartino,et al.  Binding and Functional Properties of Recombinant and Endogenous CXCR3 Chemokine Receptors* , 1998, The Journal of Biological Chemistry.

[26]  A. Gottlieb,et al.  Detection of a gamma interferon-induced protein IP-10 in psoriatic plaques , 1988, The Journal of experimental medicine.

[27]  D. Patel,et al.  CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. , 2001, Clinical immunology.

[28]  B. Sillion,et al.  Synthesis of 4H-3,1-benzoxazin-4-ones and 4-(3H)quinazolinones from anthranilic acids and their derivatives by the use of triphenyl phosphite and pyridine , 1980 .

[29]  A. Luster,et al.  Donor-Derived Ip-10 Initiates Development of Acute Allograft Rejection , 2001, The Journal of experimental medicine.

[30]  D. Kaufman,et al.  Genetic deletion of chemokine receptor CXCR3 or antibody blockade of its ligand IP-10 modulates posttransplantation graft-site lymphocytic infiltrates and prolongs functional graft survival in pancreatic islet allograft recipients. , 2003, Surgery.

[31]  I. D. de Esch,et al.  Synthesis and structure-activity relationship of 3-phenyl-3H-quinazolin-4-one derivatives as CXCR3 chemokine receptor antagonists. , 2005, Bioorganic & medicinal chemistry letters.

[32]  F. Rea,et al.  Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. , 2001, The American journal of pathology.

[33]  F. Thaiss,et al.  CXCR3 and CCR5 Positive T-Cell Recruitment in Acute Human Renal Allograft Rejection , 2004, Transplantation.

[34]  Jakob S. Jensen,et al.  Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. , 1999, The Journal of clinical investigation.

[35]  M. Baggiolini,et al.  Short Communication Increased Expression of IP-10, IL-8, MCP-1, and MCP-3 in Ulcerative Colitis , 1999 .

[36]  D. Owen,et al.  Identification and structure-activity relationships of 1-aryl-3-piperidin-4-yl-urea derivatives as CXCR3 receptor antagonists. , 2007, Bioorganic & medicinal chemistry letters.

[37]  Maria L Webb,et al.  Identification and initial evaluation of 4-N-aryl-[1,4]diazepane ureas as potent CXCR3 antagonists. , 2006, Bioorganic & medicinal chemistry letters.

[38]  A. Luster,et al.  IP-10-induced recruitment of CXCR3 host T cells is required for small bowel allograft rejection. , 2004, Gastroenterology.

[39]  R. Homer,et al.  Regulation of pulmonary fibrosis by chemokine receptor CXCR3. , 2004, The Journal of clinical investigation.

[40]  J. Farber.  Mig and IP‐10: CXC chemokines that target lymphocytes , 1997, Journal of leukocyte biology.

[41]  J. Newcombe,et al.  Expression of the interferon‐γ‐inducible chemokines IP‐10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions , 2000, Neuropathology and applied neurobiology.

[42]  James G. Boyd,et al.  Interferon–inducible T Cell Alpha Chemoattractant (I-TAC): A Novel Non-ELR CXC Chemokine with Potent Activity on Activated T Cells through Selective High Affinity Binding to CXCR3 , 1998, The Journal of experimental medicine.

[43]  M. Fishbein,et al.  Elevated Serum Levels of the CXCR3 Chemokine ITAC Are Associated With the Development of Transplant Coronary Artery Disease , 2003, Circulation.

[44]  C. Mackay,et al.  Chemokine receptors and T cell chemotaxis , 1996, The Journal of experimental medicine.

[45]  R. Leurs,et al.  Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). , 1999, The Journal of investigative dermatology.